Related references
Note: Only part of the references are listed.Treatment-free remission in patients with chronic myeloid leukemia
Delphine Rea et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells
Hu Lei et al.
LEUKEMIA RESEARCH (2018)
Hereditary diffuse gastric cancer: One family's story
Haley M. Zylberberg et al.
WORLD JOURNAL OF CLINICAL CASES (2018)
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
Susanne Isfort et al.
JOURNAL OF BLOOD MEDICINE (2018)
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study
Delphine Rea et al.
BLOOD (2017)
Late mitotic functions of Aurora kinases
Olga Afonso et al.
CHROMOSOMA (2017)
Hereditary diffuse gastric cancer in two families: A case report
Irene Feroce et al.
ONCOLOGY LETTERS (2017)
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel
Martin C. Mueller et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Second Tyrosine Kinase Inhibitor Discontinuation Attempt in Patients With Chronic Myeloid Leukemia
Laurence Legros et al.
CANCER (2017)
The chronic myeloid leukemia stem cell: stemming the tide of persistence
Tessa L. Holyoake et al.
BLOOD (2017)
Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples
Anna Kazarian et al.
BRITISH JOURNAL OF CANCER (2017)
Preventing E-cadherin aberrant N-glycosylation at Asn-554 improves its critical function in gastric cancer
S. Carvalho et al.
ONCOGENE (2016)
Treatment of chronic myelogenous leukemia
Christine Kujak et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
Elias Jabbour et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
BCR-ABL1 mutation ≠ ponatinib resistance
Giuseppe Saglio et al.
BLOOD (2016)
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Sung-Eun Lee et al.
HAEMATOLOGICA (2016)
Aurora-A Kinase: A Potent Oncogene and Target for Cancer Therapy
Min Yan et al.
MEDICINAL RESEARCH REVIEWS (2016)
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study
Sung-Eun Lee et al.
HAEMATOLOGICA (2016)
Current developments in molecular monitoring in chronic myeloid leukemia
Justine Ellen Marum et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers
Rachel S. van der Post et al.
JOURNAL OF MEDICAL GENETICS (2015)
Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase
Xu Liu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Familial gastric cancer: genetic susceptibility, pathology, and implications for management
Carla Oliveira et al.
LANCET ONCOLOGY (2015)
Epigenetic regulation of DNA repair machinery in Helicobacter pylori-induced gastric carcinogenesis
Juliana Carvalho Santos et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Milestones and Monitoring
Alessandro Morotti et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
Hereditary Diffuse Gastric Cancer Syndrome CDH1 Mutations and Beyond
Samantha Hansford et al.
JAMA ONCOLOGY (2015)
被撤回的出版物: Recurrent Glioblastoma: Where we stand(Retracted article. See vol. 6, pg. 153, 2017)
Sanjoy Roy et al.
SOUTH ASIAN JOURNAL OF CANCER (2015)
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
Elias Jabbour et al.
BLOOD (2014)
Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease
Philippe Rousselot et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Breast-Cancer Risk in Families with Mutations in PALB2
A. C. Antoniou et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Patient-reported disease knowledge and educational needs in Lynch syndrome: findings of an interactive multidisciplinary patient conference
Sarah A. Bannon et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2014)
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani et al.
BLOOD (2013)
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M. Ross et al.
BLOOD (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The Growing Arsenal of ATP-Competitive and Allosteric Inhibitors of BCR-ABL
Oliver Hantschel et al.
CANCER RESEARCH (2012)
Cancer Epigenetics: A Brief Review
Shami Virani et al.
ILAR JOURNAL (2012)
The Epigenotype
C. H. Waddington
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2012)
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
F. X. Gruber et al.
LEUKEMIA (2012)
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
B. Hanfstein et al.
LEUKEMIA (2012)
Standardized definitions of molecular response in chronic myeloid leukemia
N. C. P. Cross et al.
LEUKEMIA (2012)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Regulation of chromatin by histone modifications
Andrew J. Bannister et al.
CELL RESEARCH (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
V. Grossmann et al.
LEUKEMIA (2011)
Drug therapy for hereditary cancers
Evgeny N. Imyanitov et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2011)
A novel truncating mutation in the E-cadherin gene in the first Iranian family with hereditary diffuse gastric cancer
S. R. Ghaffari et al.
EJSO (2010)
Germline mutation of the E-cadherin gene in three sibling cases with advanced gastric cancer: clinical consequences for the other family members
Beate Mayrbaeurl et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2010)
Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice
Parry Guilford et al.
GASTRIC CANCER (2010)
Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research
Rebecca C. Fitzgerald et al.
JOURNAL OF MEDICAL GENETICS (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Epigenetic modifications and human disease
Anna Portela et al.
NATURE BIOTECHNOLOGY (2010)
Principles and challenges of genome-wide DNA methylation analysis
Peter W. Laird
NATURE REVIEWS GENETICS (2010)
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2010)
Chronic Myeloid Leukemia: A Historical Perspective
John M. Goldman
SEMINARS IN HEMATOLOGY (2010)
MGMT promoter methylation in malignant gliomas
Markus J. Riemenschneider et al.
TARGETED ONCOLOGY (2010)
Intercellular Junction Assembly, Dynamics, and Homeostasis
Kathleen J. Green et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Temozolomide in malignant gliomas: current use and future targets
J. Lee Villano et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
E-cadherin mutations and cell motility: A genotype-phenotype correlation
Ana Rita Mateus et al.
EXPERIMENTAL CELL RESEARCH (2009)
Discovery and Development of Aurora Kinase Inhibitors as Anticancer Agents
John R. Pollard et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
L. L. Remsing Rix et al.
LEUKEMIA (2009)
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL:: In vitro and in vivo studies
Daigo Akahane et al.
CANCER SCIENCE (2008)
The cell-cell adhesion molecule E-cadherin
F. van Roy et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia
Jane F. Apperley
LANCET ONCOLOGY (2007)
Characterization of the P373L E-cadherin germline missense mutation and implication for clinical management
G. Corso et al.
EJSO (2007)
An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR
Martin C. Mueller et al.
HAEMATOLOGICA (2007)
Structural basis for potent inhibition of the Aurora kinases and a T3151 multi-drug resistant mutant form of Abl kinase by VX-680
G. M. T. Cheetham et al.
CANCER LETTERS (2007)
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation
Francis J. Giles et al.
BLOOD (2007)
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Philippe Rousselot et al.
BLOOD (2007)
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors:: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy Hughes et al.
BLOOD (2006)
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
TA Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
CDH1 associated gastric cancer: a report of a family and review of the literature
CJ Moran et al.
EJSO (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment
JM Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma
JC Machado et al.
GASTROENTEROLOGY (2003)
Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred
C Oliveira et al.
HUMAN MUTATION (2002)
Initial sequencing and analysis of the human genome
ES Lander et al.
NATURE (2001)
Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer
WM Grady et al.
NATURE GENETICS (2000)
Share Paper
